Saeed Sadeghi MD

Hematologic Oncology

Professor, Medicine, UCLA School of Medicine

2020 Santa Monica BoulevardSuite 230Santa Monica, CA 90404
Phone+1 310-829-5471
Fax+1 310-582-6294

Dr. Sadeghi is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sadeghi's full profile Already have an account?

Summary

Dr. Saeed Sadeghi is an oncologist based in Santa Monica, CA, specializing in hematologic oncology. He completed his medical education at Saint Louis University School of Medicine, followed by a residency in internal medicine at USC/LA General, and a fellowship in hematology and medical oncology at UCLA. His expertise includes amyloidosis, myelodysplasia, myelofibrosis, and Hodgkin's lymphoma. Dr. Sadeghi has published several research papers, including work on ovarian cancer resistance, hepatocellular carcinoma, and cholangiocarcinoma. He has been involved in clinical trials focused on cancer treatments, including studies on Xentuzumab and BGJ398. He received honors for his proficiency in electronic health records, obtaining CMS Meaningful Use Stage 1 and 2 Certifications.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1999 - 2002
Saint Louis University School of MedicineClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2000 - 2028
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Start of enrollment: 2014 Jul 23
TERMINATED
PHASE2
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer Start of enrollment: 2017 May 04
COMPLETED
PHASE1

Publications & Presentations

PubMed

Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology.
Angela Misic, Ghadi Ghanem, Saeed Sadeghi, Matthew Carroll
Thrombosis Journal. 2026-06-19
2 citations
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.
Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, Jyoti Malhotra, Saeed Sadeghi
NPJ Precision Oncology. 2026-02-28
3 citations
Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
Zev A Wainberg, Jason M Link, Alykhan Premji, Serena Zheng, Michael Srienc
Nature Communications. 2026-01-31